COMPOSITIONS FOR THE TREATMENT OF VIRAL PULMONARY INFECTIONS

Abstract

The disclosure relates to a method for treating a viral pulmonary infection (e.g., COVID-19 infection), the method comprising the step of delivering a composition comprising at least one bronchodilator or a pharmaceutically acceptable salt thereof and at least one pulmonary surfactant or a pharmaceutically acceptable salt thereof to the airway of a subject in need of treatment for the pulmonary viral infection.

Claims

1. A method for treating pulmonary inflammation comprising administering a pharmaceutical composition to the airway of a subject in need thereof, wherein the composition consists of: albuterol or a pharmaceutically acceptable salt thereof; 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphoglycerol (POPG) or a pharmaceutically acceptable salt thereof; and at least one of a solvent, a propellant, and an excipient; wherein: the albuterol and the POPG are the sole therapeutic agents.

2. The method of claim 1, wherein the pulmonary inflammation is caused by a coronavirus.

3. The method of claim 2, wherein the pulmonary inflammation is caused by SARS-CoV-2.

4. The method of claim 1, wherein the airway is the upper airway.

5. The method of claim 1, wherein the airway is the lower airway.

6. The method of claim 1, wherein the airway is the lungs.

7. The method of claim 1, wherein the composition is an aerosolized composition.

8. The method of claim 1, wherein the composition is administered with an inhalation device.

9. The method of claim 1, wherein the composition is administered with a dry powder inhaler (DPI),metered dose inhaler (MDI), a sprayer, a nebulizer, or a dry powder generator.

10. The method of claim 1, wherein the albuterol is albuterol sulfate.

11. The method of claim 1, wherein the excipient is a solubilizing agent or a suspension stabilizer.

12. The method of claim 1, wherein the solvent comprises ethanol.

13. The method of claim 1, wherein the excipient is an additional surfactant.

14. The method of claim 1, wherein the propellant comprises at least one of a chlorofluorocarbon, a hydrochlorofluorocarbon or a hydrofluorocarbon.

15. The method of claim 1, wherein the propellant comprises at least one of trichlorofluoromethane, dichlorodifluoromethane, dichlorotetrafluoroethanol 1,1,1,2-tetrafluoroethane, FIFA-134a (hydrofluroalkane-134a), and FIFA-227 (hydrofluroalkane-227).

16. The method of claim 1, wherein the composition is administered to the airway of the subject as an aerosol.

17. The method of claim 16, wherein the aerosol comprises particles having a size of less than about 10 μm.

18. The method of claim 1, wherein the composition is a solution or a suspension.

Description

EXAMPLES

[0061] The disclosure can be better understood by reference to the following examples which are offered by way of illustration. The disclosure is not limited to the examples given herein.

[0062] An example of a composition comprising at least one bronchodilator and at least one pulmonary surfactant is shown in Table 1.

TABLE-US-00001 TABLE 1 Component % w/w CAS # POPG/PI 1.3 185435-28-3  Albuterol Sulfate 0.1  51022-70-9  Normal Saline 0.9  7647-14-5.